Moderna, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Salveen Richter from Goldman Sachs maintained a Hold rating on the stock and has a $33.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Salveen Richter’s rating is based on a combination of factors that influence Moderna’s future growth prospects. The company has projected a revenue growth of up to 10% year-over-year in 2026, supported by established partnerships in countries like the UK, Canada, and Australia. These partnerships are expected to provide a steady revenue stream from respiratory vaccines, including the next-generation COVID vaccine, mNEXSPIKE. However, the projected growth rate by Goldman Sachs is slightly lower at 5.3%, indicating some level of uncertainty.
Additionally, Moderna is focusing on expanding its oncology vertical and leveraging AI across its operations to enhance productivity. Despite these positive developments, there are ongoing legal challenges concerning the use of LNP technology, which could pose risks to the company’s future performance. Given these mixed factors, the Hold rating reflects a cautious approach, acknowledging both the potential for growth and the existing uncertainties.
According to TipRanks, Richter is a 4-star analyst with an average return of 11.4% and a 45.34% success rate. Richter covers the Healthcare sector, focusing on stocks such as Moderna, Biogen, and Alnylam Pharma.
In another report released on December 7, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $29.00 price target.